Acta Chir Orthop Traumatol Cech. 2020; 87(4):292-296 | DOI: 10.55095/achot2020/044

Tetanus Still CurrentCase report

A. CHRDLE1,2,3,*, M. BALEJOVÁ4
1 Infekční oddělení, Nemocnice České Budějovice, a.s.
2 Royal Liverpool University Hospital, Liverpool, Velká Británie
3 Zdravotně sociální fakulta Jihočeské univerzity v Českých Budějovicích
4 Laboratoř klinické mikrobiologie, Nemocnice České Budějovice, a.s.

Tetanus is a disease caused by tetanotoxin produced in necrotic wounds by Clostridium tetani. It is a very rare disease in Czechia due to successful and effective population-wide vaccination programme, despite the fact that spores of C. tetani are permanently present in the environment. Groups with the highest risk of clinical tetanus include elderly people, immunocompromised individuals, residents of foreign origin with unclear vaccination history, and unvaccinated children. We present four case studies of severe and mild form of tetanus, wound infection with the presence of C. tetani without the development of clinical tetanus in a fully vaccinated individual, and unexpected risk of tetanus in an unvaccinated child. Due to the rare occurrence of tetanus in Czechia, the clinical awareness of the risk of tetanus decreases as well as the clinical experience with diagnosis of early or mild forms of tetanus. Communication skills during the management of contaminated wounds play a critical role in the decision who should get tetanus anatoxin only and who should get antitetanus immunoglobulin along with the active immunization by tetanus anatoxin.

Keywords: tetanus, Clostridium tetani, vaccination, postexposure prophylaxis, vaccine hesitancy, contaminated wounds

Published: August 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
CHRDLE A, BALEJOVÁ M. Tetanus Still Current. Acta Chir Orthop Traumatol Cech. 2020;87(4):292-296. doi: 10.55095/achot2020/044. PubMed PMID: 32940226.
Download citation

References

  1. Aziz R, Colombe S, Mwakisambwe G, Ndezi S, Todd J, Kalluvya S, Mangat HS, Magleby R, Koebler A, Kenemo B, Peck RN, Downs JA. Pre-post effects of a tetanus care protocol implementation in a sub-Saharan African intensive care unit. PLoS Negl Trop Dis. 2018;12:e0006667. Go to original source... Go to PubMed...
  2. Danova J, Kocourkova A, Celko AM. Active surveillance study of adverse events following immunisation of children in the Czech Republic. BMC Public Health. 2017;17:167. Go to original source... Go to PubMed...
  3. Doporučení Národní imunizační komise k očkování proti tetanu v dospělosti. https://www.mzcr.cz/Verejne/dokumenty/doporuceni-niko-k-ockovani-proti-tetanu-v-dospelosti2-52013-_7786_1985_5.html
  4. European Centre for Disease Prevention and Control. Tetanus. In: ECDC. Annual epidemiological report for 2017. ECDC, Stockholm, 2019.
  5. Grundy J, Biggs BA. The impact of conflict on immunisation coverage in 16 countries. Int J Health Policy Manag. 2019;8:211-221. Go to original source... Go to PubMed...
  6. Holý, O., Vlčková, J., Janoušková, L., Matoušková, I. Prevalence difterie, tetanu a pertuse ve světě. Klin Mikrobiol Inf Lék. 2017;23:10-16.
  7. Kyu HH, Mumford JE, Stanaway JD, Barber RM, Hancock JR, Vos T, Murray CJ, Naghavi M. Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. BMC Public Health. 2017;17:179. Go to original source... Go to PubMed...
  8. Public Health England. Tetanus. Guidance on the management of suspected cases and on the assessment and management tetanus-prone wounds. July 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/820628/Tetanus_information_for_health_professionals_2019.pdf
  9. Rámcový evropský Souhrn údajů o přípravku obsahujících lidský antitetanický imunoglobulin. https://www.ema.europa.eu/en/documents/scientific-guideline/core-spc-human-tetanus-immunoglobulin-intramuscular-use-cpmp/bpwg/3730/02_en.pdf
  10. Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus: an evidence-based review. Crit Care. 2014;18:217. Go to original source... Go to PubMed...
  11. Schallehn G, Wolf MH. [Morfological changes in human embryonic lung fibroblasts caused by cytotoxins of various Clostridium species]. Zentralbl Bakteriol Mikrobiol Hyg A. 1988;267:367-378. Go to original source...
  12. Souhrn údajů o přípravku Tetavax. http://www.sukl.cz/modules/medication/detail.php?code=0083443&tab=texts
  13. Souhrn údajů o přípravku Vacteta. http://www.sukl.cz/modules/medication/detail.php?code=0208575&tab=texts
  14. Svoboda J. Dva případy tetanu. Acta Chir Orthop Traumatol Cech. 1950;17:289-292. Go to PubMed...
  15. Státní zdravotní ústav. Vybrané infekční nemoci v ČR v letech 2008-2017 - absolutně. http://www.szu.cz/publikace/data/2017/vybrane-infekcni-nemoci-v-cr-v-letech-2008-2017-absolutne
  16. Udwadia FE. Epidemiology. In: Udwadia FE (ed). Tetanus. Vol. 1, Oxford University Press, Bombay, 1994, pp.7-18.
  17. Vyhláška č. 537/2006 Sb. Vyhláška o očkování proti infekčním nemocem, v aktuálním znění, verze 1.1.2018, https://www.zakonyprolidi.cz/cs/2006-537
  18. Yen LM, Thwaites CL. Tetanus. Lancet. 2019;393:1657-1668. Go to original source... Go to PubMed...